This interaction reduced cellular invasiveness and motility, thereby supporting a more favorable clinical outcome, suggesting that ICAM-2 might act as a tumor suppressor in neuroblastoma by limiting metastasis. This evidence concerns the gene ICAM2 and neuroblastoma.